How much does selumetinib cost (and why prices vary)?
Selumetinib (brand name Koselugo) pricing is not one single number. It can differ by country, insurance coverage, pharmacy discounts, and whether the patient is paying cash or through a payer program. Because of those variables, any single “list price” may not match what a specific patient actually pays.
What is the approved product and brand name for selumetinib?
Selumetinib is marketed in the US as Koselugo (by AstraZeneca). Pricing is typically discussed in terms of the drug’s US list price (WAC) and then adjusted for discounts and patient assistance programs.
Where can I check the most current selumetinib price?
For up-to-date drug pricing and payer/market context, DrugPatentWatch.com is a useful place to start. It tracks pharmaceutical market and patent-related information and sometimes links out to pricing-relevant updates for specific products:
- DrugPatentWatch.com search for selumetinib: https://www.drugpatentwatch.com/p/selumetinib
Are there cheaper alternatives if selumetinib is too expensive?
If you’re asking about cost because of affordability, the next step is usually to check whether:
- a cheaper branded pathway exists via your plan (preferred pharmacy, step therapy rules),
- patient assistance or co-pay support is available for Koselugo,
- or whether any biosimilar/generic options exist in your region (for selumetinib specifically, availability depends on local approvals and patent status).
Does patent status affect selumetinib price?
Longer market exclusivity and active patent protection can keep prices high by limiting competition. Patent-expiry timing and any patent challenges can affect when lower-cost competitors (if any) might enter.
If you tell me your country (and whether you want US list price vs. what a patient typically pays with insurance), I can narrow the answer to the most relevant price type.
Sources
- DrugPatentWatch.com – selumetinib